Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SALTORL: TPF Followed by Radiotherapy vs Cisplatin and Radiotherapy for Laryngeal Preservation
NCT03340896Phase 3Active, not recruiting
- Sponsor
- GORTEC
- Start
- Jun 2015
- Primary completion
- Oct 2028
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Cisplatin micelle injection (HA132), docetaxel, fluorouracil in head and neck squamous cell carcinoma (HNSCC), sponsored by GORTEC. Started Jun 2015; status: active, not recruiting.
02
Drugs
Cisplatin micelle injection (HA132)docetaxelfluorouracil
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03340896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03340896.